Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Delcath Systems Inc (NASDAQ:DCTH)

Delayed Data
As of Nov 25
 +0.01 / +2.27%
Today’s Change
Today|||52-Week Range
Health Technology
Medical Specialties

Company Description

Delcath Systems, Inc. is a pharmaceutical and medical device company, which is focused on oncology and liver cancer therapy. Its proprietary drug and device combination product, Delcath Hepatic Delivery System is designed to administer high dose chemotherapy and other therapeutic agents to the liver, while controlling the systemic exposure of those agents. The company also initiated plans to investigate the Melblez kit for primary liver cancer; and focuses on the treatment of primary and metastatic liver cancers. Its proprietary product also delivers and filters melphalan hydrochloride under the trade name Delcath Hepatic CHEMOSAT Delivery System. Delcath Systems was founded on August 5, 1988 and is headquartered in New York, NY.

Contact Information

Delcath Systems, Inc.
1301 Avenue of the Americas
New York New York 10019
P:(212) 489-2100
Investor Relations:



Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Jennifer K. SimpsonPresident, Chief Executive Officer & Director
Barbra C. KeckCFO, Secretary, CAO, VP & Controller
J. Chris HouchinsSenior Vice President-Clinical & Medical Affairs
Jason A. RifkinVice President-Commercial Programs
John PurpuraEVP-Regulatory Affairs & Quality Assurance